Eyebright Medical Financials
688050 Stock | 90.61 1.90 2.05% |
Operating Margin 0.3314 | PE Ratio 47.441 | Profit Margin 0.2721 | Payout Ratio 0.187 | EPS Estimate Current Quarter 0.46 |
Eyebright | Select Account or Indicator |
Understanding current and past Eyebright Medical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Eyebright Medical's financial statements are interrelated, with each one affecting the others. For example, an increase in Eyebright Medical's assets may result in an increase in income on the income statement.
Please note, the presentation of Eyebright Medical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Eyebright Medical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Eyebright Medical's management manipulating its earnings.
Eyebright Medical Stock Summary
Eyebright Medical competes with Great Sun, SUNSEA Telecommunicatio, Guangdong Shenglu, Guangxi Wuzhou, and Jiahe Foods. Eyebright Medical is entity of China. It is traded as Stock on SHG exchange.Specialization | Health Care, Health Care Equipment & Services |
Instrument | China Stock View All |
Exchange | Shanghai Stock Exchange |
ISIN | CNE1000041J5 |
Business Address | Changping Science Technology |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.ebmedical.com |
Phone | 86 10 6074 5730 |
You should never invest in Eyebright Medical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Eyebright Stock, because this is throwing your money away. Analyzing the key information contained in Eyebright Medical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Eyebright Medical Key Financial Ratios
Eyebright Medical's financial ratios allow both analysts and investors to convert raw data from Eyebright Medical's financial statements into concise, actionable information that can be used to evaluate the performance of Eyebright Medical over time and compare it to other companies across industries.Revenue | 951.18 M | ||||
Gross Profit | 491.15 M | ||||
EBITDA | 506.62 M | ||||
Net Income | 304.43 M | ||||
Total Asset | 3.06 B |
Eyebright Medical Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 685.8M | 1.6B | 2.0B | 2.2B | 3.1B | 3.2B | |
Other Current Liab | 21.9M | 74.9M | 133.9M | 133.9M | 137.3K | 130.4K | |
Net Debt | (195.4M) | (536.8M) | (318.0M) | (192.1M) | (172.9M) | (181.5M) | |
Retained Earnings | 2.5M | 90.0M | 213.5M | 391.4M | 647.2M | 679.5M | |
Accounts Payable | 280.9K | 2.2M | 5.6M | 13.9M | 49.0M | 51.5M | |
Cash | 196.3M | 536.8M | 472.9M | 354.9M | 536.7M | 308.0M | |
Inventory | 60.8M | 59.1M | 56.0M | 78.8M | 181.4M | 190.4M | |
Other Current Assets | 12.9M | 466.6M | 504.1M | 11.3M | 36.5M | 34.6M | |
Total Liab | 38.3M | 90.9M | 307.5M | 324.3M | 705.9M | 741.1M | |
Total Current Assets | 334.5M | 1.1B | 1.1B | 1.1B | 1.0B | 718.5M | |
Intangible Assets | 100.6M | 112.9M | 127.8M | 140.3M | 252.2M | 264.8M | |
Common Stock | 78.8M | 78.8M | 105.1M | 105.2M | 121.0M | 93.5M |
Eyebright Medical Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Expense | 160.5K | 2.6K | 736.9K | 2.0M | 9.8M | 10.3M | |
Total Revenue | 195.2M | 273.0M | 433.1M | 579.5M | 951.2M | 998.7M | |
Gross Profit | 167.3M | 229.1M | 365.0M | 491.1M | 722.9M | 759.1M | |
Operating Income | 69.7M | 111.3M | 185.0M | 259.3M | 328.3M | 344.7M | |
Ebit | 69.7M | 111.3M | 185.0M | 259.3M | 298.2M | 313.1M | |
Research Development | 21.7M | 30.0M | 51.9M | 66.0M | 93.6M | 98.3M | |
Ebitda | 95.8M | 140.7M | 227.0M | 318.0M | 365.7M | 384.0M | |
Cost Of Revenue | 27.9M | 43.9M | 68.0M | 88.4M | 228.2M | 239.6M | |
Income Before Tax | 69.7M | 111.0M | 187.8M | 264.1M | 327.7M | 344.1M | |
Net Income | 66.7M | 96.6M | 171.3M | 232.7M | 304.0M | 319.2M | |
Income Tax Expense | 3.9M | 14.9M | 20.0M | 36.8M | 42.4M | 44.5M |
Eyebright Medical Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Eyebright Medical. It measures of how well Eyebright is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Eyebright Medical brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Eyebright had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Eyebright Medical has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (24.4M) | 1.7M | 3.3M | (22.8M) | (85.1M) | (80.9M) | |
Change In Cash | 129.4M | 340.5M | (64.0M) | (122.8M) | 181.8M | 190.8M | |
Free Cash Flow | (91.1M) | 4.6M | (91.9M) | (20.9M) | (157.7M) | (149.8M) | |
Change In Working Capital | (39.6M) | (137.1K) | 11.1M | (39.3M) | (177.9M) | (169.0M) | |
Begin Period Cash Flow | 67.0M | 196.3M | 536.8M | 472.9M | 350.0M | 234.5M | |
Other Cashflows From Financing Activities | 22.9M | 805.2M | 168.3M | (17.0M) | (19.6M) | (18.6M) | |
Depreciation | 22.4M | 26.7M | 32.0M | 43.3M | 76.7M | 80.6M | |
Other Non Cash Items | 1.9M | 707.8K | 8.4M | 18.8M | 19.3M | 12.8M | |
Dividends Paid | 265.0K | 13.0K | 30.5M | 44.4M | 61.4M | 64.4M | |
Capital Expenditures | 141.6M | 118.7M | 311.2M | 271.0M | 370.3M | 388.9M | |
Total Cash From Operating Activities | 50.5M | 123.4M | 219.3M | 250.1M | 212.6M | 122.2M | |
Net Income | 65.8M | 96.1M | 167.8M | 227.2M | 304.4M | 319.7M | |
Total Cash From Financing Activities | 14.9M | 804.7M | 137.7M | (65.1M) | (74.8M) | (71.1M) | |
End Period Cash Flow | 196.3M | 536.8M | 472.9M | 350.0M | 531.8M | 306.3M |
Eyebright Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Eyebright Medical's current stock value. Our valuation model uses many indicators to compare Eyebright Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Eyebright Medical competition to find correlations between indicators driving Eyebright Medical's intrinsic value. More Info.Eyebright Medical Technology is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.59 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Eyebright Medical Technology is roughly 1.69 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Eyebright Medical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Eyebright Medical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Eyebright Medical Systematic Risk
Eyebright Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Eyebright Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty with a total number of output elements of fourty-one. The Beta measures systematic risk based on how returns on Eyebright Medical correlated with the market. If Beta is less than 0 Eyebright Medical generally moves in the opposite direction as compared to the market. If Eyebright Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Eyebright Medical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Eyebright Medical is generally in the same direction as the market. If Beta > 1 Eyebright Medical moves generally in the same direction as, but more than the movement of the benchmark.
Eyebright Medical Technology Total Assets Over Time
Eyebright Medical Thematic Clasifications
Eyebright Medical Technology is part of several thematic ideas from IT to Drugs. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Get More Thematic IdeasEyebright Medical December 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Eyebright Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Eyebright Medical Technology. We use our internally-developed statistical techniques to arrive at the intrinsic value of Eyebright Medical Technology based on widely used predictive technical indicators. In general, we focus on analyzing Eyebright Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Eyebright Medical's daily price indicators and compare them against related drivers.
Downside Deviation | 3.38 | |||
Information Ratio | 0.0568 | |||
Maximum Drawdown | 25.04 | |||
Value At Risk | (5.45) | |||
Potential Upside | 8.39 |
Complementary Tools for Eyebright Stock analysis
When running Eyebright Medical's price analysis, check to measure Eyebright Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyebright Medical is operating at the current time. Most of Eyebright Medical's value examination focuses on studying past and present price action to predict the probability of Eyebright Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyebright Medical's price. Additionally, you may evaluate how the addition of Eyebright Medical to your portfolios can decrease your overall portfolio volatility.
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Bonds Directory Find actively traded corporate debentures issued by US companies | |
Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets |